ME Therapeutics Holdings Inc. (FRA:Q9T)

Germany · Delayed Price · Currency is EUR

0.8600

0.00 (0.00%)

At close: Jun 26, 2026

-84.78% (1Y)

Market Cap	36.90M -28.6%
Revenue (ttm)	n/a
Net Income	-857.38K
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.8650
Previous Close	0.8600
Day's Range	0.8600 - 0.8650
52-Week Range	0.7450 - 5.3500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 17, 2026

About ME Therapeutics Holdings

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company’s lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutic... [Read more]

Industry Offices and Clinics of Health Practitioners, Not Elsewhere Classified

Founded 2014

Country Canada

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol Q9T

Financial Performance

Financial numbers in CAD Financial Statements